Scholarlink

<p>The aim of this study was to describe the epidemiology of new and new persistent benzodiazepine (BZD) use following admissions to internal medicine and its relationship with patient and admission characteristics. Retrospective study that including all admissions of patients 18 years and older to Landspítali - The National University Hospital of Reykjavík, Iceland, between 2010 and 2020. BZD-naïve patients in the year preceding admission were classified into patients with new BZD use (filling one or more BZD prescriptions within 90 days of discharge), and new persistent use (filling a second prescription between 90 and 180 days). Among 54,844 eligible admissions, 6.3% (3471/54,844) initiated new use, and of those 39.4% (95% CI 37.8–41.0) developed new persistent use. Female sex and admission to several specialties, including cardiology, gastroenterology, pulmonology, neurology, rheumatology, hematology, oncology, or palliative care were associated with an increased risk of initiating new BZD use compared with general medicine (reference group). Medium and high frailty risk was associated with reduced odds of new use. Among patients who initiated new use, the risk of initiating new persistent BZD use was higher in female patients and patients with underlying COPD as well as patients admitted to cardiology, gastroenterology, pulmonology, geriatrics, hematology, or oncology services. The incidence of new BZD use following admissions to internal medicine in Iceland is high and a large portion of patients who initiate new use transition to new persistent use. This highlights the need for strategies to reduce the likelihood of new BZD use and reduce the risk of unintended transition of new persistent BZD use to ensure appropriate short-term BZD use. Further research is needed to understand the drivers of specialty-level variation in post-discharge BZD dispensing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The incidence and clinical variables associated with new and new persistent benzodiazepine use after admission to internal medicine: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • Eyglo Soley Hrodmarsdóttir Love,
  • Freyja Jonsdottir,
  • Martin Ingi Sigurdsson

摘要

The aim of this study was to describe the epidemiology of new and new persistent benzodiazepine (BZD) use following admissions to internal medicine and its relationship with patient and admission characteristics. Retrospective study that including all admissions of patients 18 years and older to Landspítali - The National University Hospital of Reykjavík, Iceland, between 2010 and 2020. BZD-naïve patients in the year preceding admission were classified into patients with new BZD use (filling one or more BZD prescriptions within 90 days of discharge), and new persistent use (filling a second prescription between 90 and 180 days). Among 54,844 eligible admissions, 6.3% (3471/54,844) initiated new use, and of those 39.4% (95% CI 37.8–41.0) developed new persistent use. Female sex and admission to several specialties, including cardiology, gastroenterology, pulmonology, neurology, rheumatology, hematology, oncology, or palliative care were associated with an increased risk of initiating new BZD use compared with general medicine (reference group). Medium and high frailty risk was associated with reduced odds of new use. Among patients who initiated new use, the risk of initiating new persistent BZD use was higher in female patients and patients with underlying COPD as well as patients admitted to cardiology, gastroenterology, pulmonology, geriatrics, hematology, or oncology services. The incidence of new BZD use following admissions to internal medicine in Iceland is high and a large portion of patients who initiate new use transition to new persistent use. This highlights the need for strategies to reduce the likelihood of new BZD use and reduce the risk of unintended transition of new persistent BZD use to ensure appropriate short-term BZD use. Further research is needed to understand the drivers of specialty-level variation in post-discharge BZD dispensing.